Endovascular Treatment in Ischemic Stroke Follow-up Evaluation

Hopital Foch4,000 enrolled

Overview

Study like register with biomarkers samples for patient experiencing acute ischemic stroke, to assess clinical outcomes and different factors that may affect the clinical outcomes.

Study Type

OBSERVATIONAL

Enrollment

4,000

Conditions

Stroke, Acute

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 and older (i.e., candidates must have had their 18th birthday) * Neuroimaging demonstrates acute ischemic stroke with large vessel proximal with the use of neuro-thrombectomy devices intended to restore blood flow * No upper or lower limits of the neurological severity at baseline (NIHSS). * With or without intravenous thrombolysis * Oral informed consent (patient and/or trustworthy person) Non-inclusion Criteria: * Pregnant or breast-feeding women * Patient benefiting from a legal protection * Non-membership of a national insurance scheme

Locations (16)

CHU Bordeaux

Bordeaux, France

RECRUITING

CHU de Caen

Caen, France

RECRUITING

Outcomes

Primary Outcomes

Clinical outcome

modified Rankin score (mRS), score 0 to 6 with 0 = no symptoms and 6 = death.

Time frame: Day 90

Secondary Outcomes

Efficacy on reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 2b/3)

Rate of complete or near complete reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 2b/3)

Time frame: Day 1

Efficacy on revascularization (>= mTICI 2b)

Time to achieve TICI 2b or better revascularization

Time frame: Day 1

Efficacy on clinical outcome (mRS=0-1)

Rate of excellent functional outcome defined as a modified Rankin score (mRS) 0-1

Time frame: Day 90

Efficacy on functional independence (mRS 0-2)

Rate of functional independence defined as a modified Rankin score 0-2

Time frame: Day 90

Hemorrhage evaluated by imagery

Rate of symptomatic and asymptomatic intracerebral hemorrhage at MRI or CT scan

Time frame: Day 0

Hematoma rate

Rate of parenchymal hematoma 2

Time frame: Day 1

Mortality rate

Rate of all-cause mortality

Time frame: Day 90

Complication rate

Central Contacts

Elisabeth Hulier-Ammar

CONTACT

+33146251175 drci-promotion@hopital-foch.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.